<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441568</url>
  </required_header>
  <id_info>
    <org_study_id>19690</org_study_id>
    <secondary_id>2017-004334-29</secondary_id>
    <nct_id>NCT03441568</nct_id>
  </id_info>
  <brief_title>In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control</brief_title>
  <official_title>In-home Use Test of the New Modified DiprobaseÂ® Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability of the modified Diprobase formulation over 14 days
      in infants and children with a history of Atopic Dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Awaiting for business decision.
  </why_stopped>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse event (AE)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse event</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>The intensity of an AE is classified according to the following categories:
Mild
Moderate
Severe</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>BAY987534</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants and children with quiescent Atopic Dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAY987534</intervention_name>
    <description>The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.</description>
    <arm_group_label>BAY987534</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Children with normal or dry skin and a history of mild to moderate AD, but without any
             signs or symptoms within the last month prior to enrollment

          -  Skin type I - VI according to Fitzpatrick

          -  Aged 6 months to 48 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Timperley Medical Centre</name>
      <address>
        <city>Altrincham</city>
        <zip>WA14 5PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

